Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005956 · ClinicalTrials.gov registry record · NA
Biological Therapy in Treating Patients With Advanced Cancer
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT00005956: Completed NA study, sponsored by Duke University.
NCT00005956 is a NA study that has completed, run by Duke University. The registered enrollment target is 3 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005956, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
RATIONALE: A person's white blood cells mixed with tumor proteins may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of biological therapy in treating patients who have advanced cancer that shows no signs of disease following treatment.
Primary Outcome
safety
Interventions
- BIOLOGICAL therapeutic autologous dendritic cells
- BIOLOGICAL HER-2/neu intracellular domain protein
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2000-02 |
| Est. Completion | 2002-07 |
| Phase | NA |
What the finished NCT00005956 record still lists
NCT00005956 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which therapeutic autologous dendritic cells is the first listed.
NCT00005956 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00005956 about?
NCT00005956 is a clinical study titled "Biological Therapy in Treating Patients With Advanced Cancer". RATIONALE: A person's white blood cells mixed with tumor proteins may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of biological therapy in treating patients who have advanced cancer that shows no signs of disease following treatment.
What is the current status of trial NCT00005956?
This trial is currently completed. It is a NA study. The enrollment target is 3 participants. The study started on 2000-02. Estimated completion is 2002-07.
What interventions are being tested in trial NCT00005956?
The interventions under investigation include: therapeutic autologous dendritic cells (BIOLOGICAL), HER-2/neu intracellular domain protein (BIOLOGICAL).
Who is sponsoring clinical trial NCT00005956?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00005956's enrollment target sits among peer trials
3 1996th of 2000 higher than 4 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia